Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

Caroline Robert, Dirk Schadendorf, Jacob Schachter et al.|Annals of Oncology|2016

Cited by 74